PDS Biotechnology Balance Sheet Health
Financial Health criteria checks 5/6
PDS Biotechnology has a total shareholder equity of $22.0M and total debt of $24.5M, which brings its debt-to-equity ratio to 111.5%. Its total assets and total liabilities are $52.5M and $30.4M respectively.
Key information
111.5%
Debt to equity ratio
US$24.53m
Debt
| Interest coverage ratio | n/a |
| Cash | US$49.75m |
| Equity | US$22.00m |
| Total liabilities | US$30.45m |
| Total assets | US$52.45m |
Recent financial health updates
Recent updates
PDS Biotechnology: Promising Phase 2 With Cash Issues That Might Be Worth The Risk
Jan 13PDS Biotech jumps 13% as FDA clears further development of lead asset
Oct 03PDS Biotechnology files for $150 mixed shelf offering
Aug 24PDS Biotech spikes as panel backs continuation of cancer trial for lead asset
Aug 04PDS Biotechnology (NASDAQ:PDSB) Is In A Strong Position To Grow Its Business
Jul 08
PDS Biotechnology: Speculative Biotech Worth Buying After Latest Data
May 27PDS Biotechnology: Versamune Platform Targeting HPV-Associated Cancers
Feb 22PDS Biotech: Looking Attractive Despite 52-Week High Price
Sep 19PDS Biotech under pressure after pricing equity offering at $8.50
Jun 15Financial Position Analysis
Short Term Liabilities: PDSB's short term assets ($52.1M) exceed its short term liabilities ($18.3M).
Long Term Liabilities: PDSB's short term assets ($52.1M) exceed its long term liabilities ($12.1M).
Debt to Equity History and Analysis
Debt Level: PDSB has more cash than its total debt.
Reducing Debt: PDSB's debt to equity ratio has increased from 0% to 111.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: PDSB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: PDSB has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 27.6% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/05 01:31 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
PDS Biotechnology Corporation is covered by 11 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Kalpit Patel | B. Riley Securities, Inc. |